16th Annual Digestive Health Symposium

Add to Calendar 16th Annual Digestive Health Symposium 2/23/2024 8:00:00 AM 2/25/2024 12:00:00 PM America/Los_Angeles For More Details: https://uci.cloud-cme.com/course/courseoverview?EID=396 Description: This two-day format allows for the combining of three annual symposiums into one; thereby expanding our audience base, introducing attendees to all digestive health tertiary medical and surgical services offered at our Digestive Health Institute. Agenda to be uploaded The Westin Anaheim Resort false MM/DD/YYYY


Date & Location
Friday, February 23, 2024, 8:00 AM - Sunday, February 25, 2024, 12:00 PM, The Westin Anaheim Resort, Anaheim, CA

Target Audience
Specialties - Gastroenterology, Medicine
Professions - Allied Health Professional, Clinical Social Worker, EMT, Medical Assistant, Medical Student, Non-Physician, Nurse, Nurse Practitioner, Other, Pharmacist, Physical Therapist, Physician, Registered Dietitian, Resident Physician

Credits
AMA PRA Category 1 Credits™ (15.00 hours), ABIM MOC Part 2 (15.00 hours), ABS CC (15.00 hours), Non-Physician Attendance (15.00 hours)

Overview
This two-day format allows for the combining of three annual symposiums into one; thereby expanding our audience base, introducing attendees to all digestive health tertiary medical and surgical services offered at our Digestive Health Institute. Agenda to be uploaded

Objectives
At the conclusion of this activity, learners will be able to:

  1. This program will provide, thorough formal lectures, question-and-answer sessions and a hands-on workshop, updates on new approaches in the diagnosis and management of gastrointestinal, liver diseases and cancer for invasive and non-invasive methods. The methods include case-based discussion, lecture, panel, simulation, and skill-based training.
  2. Learn to manage biologic therapy around the time of surgery Improving knowledge about management of biologic therapy during surgery
  3. Understand optimization of medical therapy for inflammatory bowel disease Start to use lab testing to check drug levels.
  4. Review new drug therapies for Crohn's disease Develop better understanding of which therapies to use for Crohn's disease as we get more options
  5. Discuss cancer risk in the IBD patient Ability to discuss risk of cancer development in patients with IBD as well as more biologic and immunomodulator therapy
  6. Discuss what’s new in management of biliary and pancreatic diseases Understand the latest developments in management of biliary and pancreatic diseases
  7. To define evidence based approaches towards the diagnosis and treatment of non-cardiac chest pain, belching and potential extra-esophageal symptoms of GERD Evidence for and against GERD as a potential cause of chest pain, laryngopharyngeal symptoms and belching Evidence for and against GERD therapies for the same symptoms.
  8. Review current diagnostic and treatment paradigms for Barrett’s and esophageal cancer Develop the ideal future paradigm for detecting and treating Barrett’s and esophageal cancer. Current diagnostic and treatment paradigms for Barrett’s cancer
  9. To determine whether endoscopic therapies (TIF, Stretta, Overstitch) provide equivalent outcomes compared with anti-reflux surgery To determine the individual factors for choosing between endoscopic Evidence for traditional surgery for GERD Review of current literature regarding endoscopic therapies for GERD
  10. Which polyps to worry about, how to recognize them and how they can/should be removed Interval colorectal cancers could be reduced by over 85% by eliminating polyp miss rate and assuring complete polyp resection
  11. Incorporate advances in disease monitoring and quality metrics that should be utilized in the management of IBD patients Facilitate utilization of biologic drug monitoring to improve care of patients.
  12. Describe the medical and surgical management of perianal Crohn’s disease and know how to provide resources for patients Improved non-operative and operative management of perianal Crohn’s disease as well as more referrals for specialized
  13. Explain positioning of IBD Biologic therapies for Crohn’s disease and Ulcerative Colitis. Understanding when to refer to Tertiary care for complex cases Evidence based approach to choosing first, second and third line therapies.
  14. Upon completion of this course, participants should be able to: • Screen, diagnose, and manage viral hepatitis B • Screen, diagnose, and manage viral hepatitis C • Diagnose and manage non-alcoholic fatty liver disease • Diagnose and Manage patients with hepatocellular carcinoma By providing updated medical education, this CME program will improve the clinical knowledge and skills in managing those common chronic liver diseases.
  15. Understand the risks, benefits and appropriate utilization of the contemporary medical, surgical and endoscopic therapies for GERD patients. Evidence based approach to choosing between medical, endoscopic and surgical therapy for patients with GERD
  16. Understanding the risk of progression of pancreatic cysts. Understanding an evidence based approach to choosing an imaging modality for pancreatic cyst surveillance Understanding the appropriate approach for when to send pancreatic cysts for surgical resection Evidence based approach to choosing an imaging modality for pancreatic cyst surveillance and an approach for when to send pancreatic cysts for surgical resection
  17. Evidence base approach to understanding the pros and cons of novel weight loss and bariatric options.

Registration
Please register online at 16th Annual Digestive Health Institute Symposium (touchnet.net)
Accreditation
University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Additional Information

ADA Statement: In compliance with the Americans with Disabilities Act, we will make every reasonable effort to accommodate your request.  For any special requests, please contact the activity administrator before the meeting date.